Global Liver Cancer Diagnostic Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Liver Cancer Diagnostic Market is presumed to reach the market size of nearly USD 18258.96 Million by 2032 from USD 9389.09 Million in 2023 with a CAGR of 7.67% under the study period 2024 - 2032..

Liver cancer diagnostic refers to the methods and procedures used to detect & confirm the presence of liver cancer, also known as hepatocellular carcinoma. This diagnostic process typically involves a combination of imaging techniques, including computed tomography (CT), ultrasound, and magnetic resonance imaging (MRI), to visualize tumors and assess their extent. Blood tests, including liver function tests and biomarkers like alpha-fetoprotein (AFP), help evaluate liver health and cancer presence. An accurate diagnosis frequently necessitates a biopsy, where a tissue sample is examined microscopically for cancer cells. Timely & precise diagnosis is integral for effective treatment & better outcomes.

Market Dynamics

The liver cancer diagnostic market is experiencing growth fuelled by the rising prevalence of liver cancer worldwide. Factors such as rising rates of hepatitis B & C infections, increasing alcohol consumption, and obesity contribute to the growing incidence of liver cancer, leading to heightened demand for effective diagnostic solutions. Early detection enhances treatment outcomes, thereby driving the need for advanced diagnostic technologies. Technological advancements present significant opportunities in the market. Innovations in imaging techniques, such as high-resolution MRI and advanced ultrasound technologies, provide more accurate and detailed visualization of liver tumors. Additionally, developing non-invasive diagnostic tests, such as liquid biopsies and molecular biomarkers, offers promising alternatives to traditional biopsy methods, improving patient comfort and diagnostic accuracy.

The growing emphasis on personalized medicine in oncology creates further opportunities for liver cancer diagnostics. Genetic and genomic testing advances allow for identifying specific tumor profiles and mutations, enabling tailored treatment approaches and improving patient management. This trend supports the demand for advanced diagnostic tools that provide comprehensive molecular and genetic information. Expanding healthcare infrastructure and increasing healthcare investments in emerging markets contribute to market growth. As these regions develop their healthcare systems and increase access to diagnostic technologies, the demand for liver cancer diagnostics is expected to rise. Moreover, the rise of awareness and education programs regarding liver cancer and its risk factors enhances early detection efforts. Public health initiatives that promote screening and early diagnosis further support market growth by increasing the adoption of diagnostic tests. However, high costs associated with advanced diagnostic technologies and limited access to healthcare in underserved regions can restrain market growth.

This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter's five forces analysis, market attractiveness analysis and value chain analysis. These tools are employed to gain insights of the potential value of the market facilitating the business strategists with the latest growth opportunities. Additionally, these tools also provide a detailed analysis of each application/product segment in the global market of liver cancer diagnostic.

Market Segmentation

The broad liver cancer diagnostic market has been sub-grouped into test type and end-user. The report studies these subsets with respect to the geographical segmentation. The strategists can gain a detailed insight and devise appropriate strategies to target specific market. This detail will lead to a focused approach leading to identification of better opportunities.

By Test Type

Laboratory Tests (Biomarkers, Blood Tests)
Imaging
Endoscopy
Biopsy
Others

By End-use

Hospitals & Diagnostic Laboratories
Academic & Research Institutes
Pharmaceutical & CRO Laboratories
Regional Analysis
Furthermore, the report comprises of the geographical segmentation which mainly focuses on current and forecast demand for liver cancer diagnostic in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The report further focuses on demand for individual application segments in all the regions.
The report also covers detailed competitive landscape including company profiles of key players operating in the global market. The key players in the Liver Cancer Diagnostic market includes Abbott Laboratories, F. Hoffmann-La Roche Ltd., Qiagen N.V., Thermo Fisher Scientific Inc., Siemens Healthineers, Becton Dickinson & Company, Illumina Inc., Koninklijke Philips N.V, Epigenomics AG, Fujifilm Medical Systems U.S.A. Inc. An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR11210557

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. LIVER CANCER DIAGNOSTIC - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Test Type
- 3.7.2 Market Attractiveness Analysis By End-use
- 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL LIVER CANCER DIAGNOSTIC MARKET ANALYSIS BY TEST TYPE

5.1. Overview By Test Type
5.2. Historical and Forecast Data
5.3. Analysis By Test Type
5.4. Laboratory Tests (Biomarkers, Blood Tests) Historic and Forecast Sales By Regions
5.5. Imaging Historic and Forecast Sales By Regions
5.6. Endoscopy Historic and Forecast Sales By Regions
5.7. Biopsy Historic and Forecast Sales By Regions
5.8. Others Historic and Forecast Sales By Regions

6. GLOBAL LIVER CANCER DIAGNOSTIC MARKET ANALYSIS BY END-USE

6.1. Overview By End-use
6.2. Historical and Forecast Data
6.3. Analysis By End-use
6.4. Hospitals & Diagnostic Laboratories Historic and Forecast Sales By Regions
6.5. Academic & Research Institutes Historic and Forecast Sales By Regions
6.6. Pharmaceutical & CRO Laboratories Historic and Forecast Sales By Regions

7. GLOBAL LIVER CANCER DIAGNOSTIC MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1 Overview, Historic and Forecast Data Sales Analysis
- 7.3.2 North America By Segment Sales Analysis
- 7.3.3 North America By Country Sales Analysis
- 7.3.4 United States Sales Analysis
- 7.3.5 Canada Sales Analysis
- 7.3.6 Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1 Overview, Historic and Forecast Data Sales Analysis
- 7.4.2 Europe By Segment Sales Analysis
- 7.4.3 Europe By Country Sales Analysis
- 7.4.4 United Kingdom Sales Analysis
- 7.4.5 France Sales Analysis
- 7.4.6 Germany Sales Analysis
- 7.4.7 Italy Sales Analysis
- 7.4.8 Russia Sales Analysis
- 7.4.9 Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1 Overview, Historic and Forecast Data Sales Analysis
- 7.5.2 Asia Pacific By Segment Sales Analysis
- 7.5.3 Asia Pacific By Country Sales Analysis
- 7.5.4 China Sales Analysis
- 7.5.5 India Sales Analysis
- 7.5.6 Japan Sales Analysis
- 7.5.7 South Korea Sales Analysis
- 7.5.8 Australia Sales Analysis
- 7.5.9 South East Asia Sales Analysis
- 7.5.10 Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1 Overview, Historic and Forecast Data Sales Analysis
- 7.6.2 Latin America By Segment Sales Analysis
- 7.6.3 Latin America By Country Sales Analysis
- 7.6.4 Brazil Sales Analysis
- 7.6.5 Argentina Sales Analysis
- 7.6.6 Peru Sales Analysis
- 7.6.7 Chile Sales Analysis
- 7.6.8 Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1 Overview, Historic and Forecast Data Sales Analysis
- 7.7.2 Middle East & Africa By Segment Sales Analysis
- 7.7.3 Middle East & Africa By Country Sales Analysis
- 7.7.4 Saudi Arabia Sales Analysis
- 7.7.5 UAE Sales Analysis
- 7.7.6 Israel Sales Analysis
- 7.7.7 South Africa Sales Analysis
- 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE LIVER CANCER DIAGNOSTIC COMPANIES

8.1. Liver Cancer Diagnostic Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9. COMPANY PROFILES OF LIVER CANCER DIAGNOSTIC INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Abbott Laboratories
- 9.3.1 Company Overview
- 9.3.2 Company Revenue
- 9.3.3 Products
- 9.3.4 Recent Developments
9.4. F. Hoffmann-La Roche Ltd.
- 9.4.1 Company Overview
- 9.4.2 Company Revenue
- 9.4.3 Products
- 9.4.4 Recent Developments
9.5. Qiagen N.V.
- 9.5.1 Company Overview
- 9.5.2 Company Revenue
- 9.5.3 Products
- 9.5.4 Recent Developments
9.6. Thermo Fisher Scientific Inc.
- 9.6.1 Company Overview
- 9.6.2 Company Revenue
- 9.6.3 Products
- 9.6.4 Recent Developments
9.7. Siemens Healthineers
- 9.7.1 Company Overview
- 9.7.2 Company Revenue
- 9.7.3 Products
- 9.7.4 Recent Developments
9.8. Becton Dickinson & Company
- 9.8.1 Company Overview
- 9.8.2 Company Revenue
- 9.8.3 Products
- 9.8.4 Recent Developments
9.9. Illumina Inc.
- 9.9.1 Company Overview
- 9.9.2 Company Revenue
- 9.9.3 Products
- 9.9.4 Recent Developments
9.10. Koninklijke Philips N.V
- 9.10.1 Company Overview
- 9.10.2 Company Revenue
- 9.10.3 Products
- 9.10.4 Recent Developments
9.11. Epigenomics AG
- 9.11.1 Company Overview
- 9.11.2 Company Revenue
- 9.11.3 Products
- 9.11.4 Recent Developments
9.12. Fujifilm Medical Systems U.S.A. Inc.
- 9.12.1 Company Overview
- 9.12.2 Company Revenue
- 9.12.3 Products
- 9.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies